| P2093 | author name string | Rossi JJ | |
| P2860 | cites work | HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor | Q22242268 |
| | Identification of a major co-receptor for primary isolates of HIV-1 | Q22251282 |
| | A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1 | Q24683706 |
| | The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme | Q28262778 |
| | The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates | Q28282895 |
| | CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1 | Q28646859 |
| | In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector | Q29547503 |
| | Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene | Q29614892 |
| | Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of tetrahymena | Q29615409 |
| | HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 | Q29616094 |
| | Decay characteristics of HIV-1-infected compartments during combination therapy | Q29619375 |
| | Prognosis in HIV-1 infection predicted by the quantity of virus in plasma | Q29619980 |
| | Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes | Q34599861 |
| | Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. | Q34719998 |
| | Catalytic antisense RNA (ribozymes): their potential and use as anti-HIV-1 therapeutic agents. | Q35773661 |
| | Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates | Q35927204 |
| | Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. | Q36634983 |
| | A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread | Q37311199 |
| | Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition | Q38363343 |
| | Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells | Q38933102 |
| | Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies | Q39177405 |
| | Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. | Q39464587 |
| | Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group | Q39490780 |
| | Practical Ribozymes: Making ribozymes work in cells | Q40393149 |
| | Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes | Q40884585 |
| | Virion encapsidation of tRNA(3Lys)-ribozyme chimeric RNAs inhibits HIV infection | Q41024276 |
| | Preclinical characterization of an anti-tat ribozyme for therapeutic application | Q41028945 |
| | Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line | Q41049538 |
| | Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals | Q41068471 |
| | Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes | Q41429788 |
| | Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector | Q41590056 |
| | Stem cells as vehicles for gene therapy: novel strategy for HIV infection | Q43684007 |
| | A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. | Q44845726 |
| | Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes | Q45869866 |
| | Use of SV40-based vectors to transduce foreign genes to normal human peripheral blood mononuclear cells | Q45881612 |
| | Sequence requirements of the hammerhead RNA self-cleavage reaction | Q54705942 |
| | Ribozymes as potential anti-HIV-1 therapeutic agents. | Q54719925 |
| | Human gene therapy | Q72882950 |
| | HIV-1 infection in an individual homozygous for the CCR5 deletion allele | Q73122336 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ribozyme | Q205858 |
| P304 | page(s) | 71-78 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | Advanced Drug Delivery Reviews | Q2825362 |
| P1476 | title | Ribozyme therapy for HIV infection | |
| P478 | volume | 44 | |